In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drugstore.com to absorb SkinStore.com

This article was originally published in The Rose Sheet

Executive Summary

Bellevue, Wash.-based Drugstore.com Inc. will acquire Salu, Inc., owner of online personal-care retailer SkinStore.com, for $36 mil., moving "one step closer toward achieving our goal of becoming the leading online retailer of beauty and spa products," firm says. According to Dec. 28 release, the half-cash, half-stock deal will close in the first quarter of 2010. SkinStore.com - which carries clinical skin-care items, sun protection products and skin health supplements - will fill out retailer's offering, which includes mass beauty products sold on Drugstore.com and the higher-end cosmetics in its Beauty.com portal, acquired in 2000 (1"The Rose Sheet" Jan. 17, 2000). Salu, expected to generate $40 million in revenue and $500,000 in net income for 2009, will continue to operate in Sacramento, Calif

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016636

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel